AVEO Oncology
A Better Life for Cancer Patients

AVEO Oncology, a commercial-stage biopharmaceutical company, is driven by its mission to improve cancer patients’ lives by identifying the areas of unmet need in the oncology space. A key factor in AVEO Oncology’s recognition as a global leader in oncology therapeutics was the U.S. approval and commercialization of its flagship drug FOTIVDA^® (tivozanib).

FOTIVDA is a differentiated VEGF receptor (VEGFR) tyrosine kinase inhibitor (TKI) that helps improve treatment efficacy and tolerability, especially in the third and fourth rounds of treatment. FOTIVDA was FDA-approved in 2021 for renal cell carcinoma (RCC) patients who have relapsed or whose cancer has become resistant to two or more systemic therapies. With this approval, FOTIVDA represents an attractive intervention and is expected to play a meaningful role in the evolving RCC treatment landscape.

While RCC treatment has advanced to a great extent and significantly improved the quality of life for patients, it has also given rise to the increasing need for proven, well-tolerated treatment options in the relapsed or refractory setting. AVEO’s pivotal phase three TIVO-3 FOTIVDA study is the first positive clinical trial in RCC patients who received two or more prior systemic therapies.

“With the introduction of FOTIVDA and the completion of TIVO-3, our pivotal phase 3 study, we provide a better tolerability profile, disease control, and effective therapy to patients,” states Michael Bailey, CEO, AVEO Oncology.

Most recently, the National Comprehensive Cancer Network^® (NCCN) has elevated FOTIVDA to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022. This is the highest categorical rating based on experience, clinical data, the data’s robustness, and the product’s overall sentiment.

“We complement our evidence based medicine with extensive patient support which ties directly back to our mission of delivering a better life to patients with cancer,” says Bailey.

AVEO Oncology’s success can also be attributed to perseverance and a commitment to build best in-class teams of dedicated employees. AVEO Oncology not only successfully commercialized FOTIVDA in the midst of the global COVID pandemic, but AVEO also filled a major unmet need in the kidney cancer patient community. Most recently, AVEO announced total Q2 2022 Net Revenue of $25.3 million and $25.0 million of FOTIVDA U.S. Net Product Revenue. This represents net product revenue growth of 24% compared with Q1 2022. Further, AVEO reaffirmed the full year 2022 FOTIVDA U.S. net product revenue guidance of $100.0 million to $110.0 million.

This kind of success can only be achieved through the efforts of an extremely skilled and dedicated team. Moving forward, AVEO Oncology is seeking both company and product acquisitions. It hopes to acquire one or more promising assets in late-stage development to add to its portfolio in the next year or two.